Stay updated with breaking news from Lai Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BeiGene is expanding its cancer drug pipeline, landing global rights to an Ensem Therapeutics cancer drug candidate ready to enter the clinic. The drug targets CDK2, an enzyme whose excessive activity is associated with cancer progression.
BeiGene has signed an agreement to acquire an exclusive worldwide license to Ensem Therapeutics’ cyclin-dependent kinase 2 (CDK2) inhibitor.
BeiGene (NASDAQ:BGNE – Free Report) had its price target cut by Morgan Stanley from $321.00 to $319.00 in a research note released on Tuesday, Benzinga reports. They currently have an overweight rating on the stock. A number of other analysts have also weighed in on BGNE. 22nd Century Group reaffirmed a downgrade rating on shares […]
StockNews.com started coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a report published on Thursday morning. The brokerage issued a hold rating on the stock. Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. raised their target price on shares of BeiGene from $297.00 to $300.00 and […]
Equities researchers at Jefferies Financial Group started coverage on shares of BeiGene (NASDAQ:BGNE – Get Free Report) in a research report issued on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $287.00 price target on the stock. Jefferies Financial Group’s price objective points to a potential upside of 49.22% from the company’s […]